Loading…
← CockpitCompetitor Analysis › KRYS Krystal Biotech, Inc.Open in the cockpit ↗

Krystal Biotech, Inc.KRYSCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Gene therapy biotech whose lead product Vyjuvek is a topical redosable gene therapy for a rare, blistering skin disease.

Momentum neutral 53
Mkt cap
$9.34B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$94.8M
20-day average traded
Fwd P/E
36.3×
forward earnings
ROIC−WACC
+25.9 pp
WACC 7.9%
Hurdle
-13 pp
Req g minus delivered
Next earnings
103 days
1 Mar 2027
Close · USD$315.34
1D+5.6%
1W+2.1%
1M-3.1%
3M-6.4%
6M+4.4%
YTD+27.9%
1Y+51.4%
ATR %3.6%
Beta0.75
52w lowhigh17.6% off high

What Krystal Biotech does

Gene therapy biotech whose lead product Vyjuvek is a topical redosable gene therapy for a rare, blistering skin disease.

Almost all revenue comes from one product, Vyjuvek, a gel applied at home that insurers pay for as a high-priced rare-disease medicine, with patients served through a central support and distribution process. US approval came in 2023, and approvals outside the US followed in 2025. Other gene therapies, including for lung disease, are still in development.

Products and services

  • Vyjuvek (dystrophic epidermolysis bullosa)
  • Pipeline: other dermatology/respiratory gene therapies

Customers

  • Dermatologists treating rare genetic skin diseases
  • Patients with epidermolysis bullosa

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Gene therapy discovery and development…

What could go right

  • Vyjuvek commercial ramp and international launches
  • Pipeline expansion into respiratory disease

What could go wrong

  • Single-product revenue concentration (Vyjuvek)
  • Small rare-disease patient population limits market size

Moat: narrow (IP / patents, regulatory licence). The first and only approved redosable topical gene therapy, on a patent-protected HSV-1 delivery vector platform.

Headquarters: Pittsburgh, Pennsylvania, US · Founded: 2016 · Employees: 295

Named competitors

Krystal Biotech at a glance

Size Krystal Biotech (KRYS) is a United States Health Care company (Biotechnology) with a market value of $9.34B, the 808th largest of 3,085 United States companies the cockpit tracks. Shares closed at $315.34 on 18 Nov 2026.

Performance Over six months the shares gained 4.4%, against +23.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 26.0% over the last twelve months (peer median +25.2%); the operating margin is 48.4% (peer median -1.9%).

Valuation It trades at 36.3× forward earnings against a peer median of 34.4× (4th most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 25.9 points above its cost of capital (7.9% WACC).

Short interest Short interest is 10.3% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026Peer median 124KRYS 104
Six months, rebased to 100: Krystal Biotech against the median of its 20 peers (local-currency closes).

Krystal Biotech financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$470M$389M$291M$50.7M$0
Revenue growth—+34%+473%——
Gross profit$437M$360M$264M$42.6M-$4.05M
EBITDA$234M$168M$110M-$92.2M-$116M
Net income$225M$205M$89.2M$10.9M-$140M
Free cash flow$310M$189M$119M-$101M-$154M
Capital expenditure$13.8M$12.0M$4.24M$11.8M$53.0M
Total debt$8.59M$9.34M$7.26M$8.09M$8.93M

Quarterly statements and history in the cockpit →

Krystal Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%PCVX1961701548002422KYMRSMMTHALOTWSTTECHTXGBMRN1093CGONAXSMIMVTELANKODSRRKBBIOKRYS6-month return →1-month return →
Up and to the right = strong over both horizons. Krystal Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×1961701548002422HALOTECHBMRN1093AXSMELANKRYSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Krystal Biotech is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%1961701548002422HALOTECHTXGBMRN1093ELANKRYSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Krystal Biotech is the large dot.

Krystal Biotech competitors and peer comparison

Head to head with its named competitors (KRYS vs ABEO vs IONS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Krystal Biotech KRYS$9.34B+4%+26%48%36.3×13.1%
Abeona Therapeutics ABEOn/a-49%n/an/an/an/a
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%n/an/a

How Krystal Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Krystal Biotech against its 20 peers (data as of 18 Nov 2026)
MeasureKRYSPeer medianRank in peer set
1-month return-3.1%-4.9%11th highest of 21
6-month return+4.4%+23.8%7th lowest of 21
Distance from 52-week high-17.6%-26.2%8th highest of 21
Revenue growth (TTM)+26.0%+25.2%8th highest of 16
Operating margin48.4%-1.9%3rd highest of 17
Forward P/E36.3×34.4×4th most expensive of 10
Growth the price implies (Req g, 7 yrs)13.1%24.6%5th least demanding of 10
Growth delivered (Del g)+26.0%+12.0%3rd highest of 10
Hurdle (Req g minus delivered)-12.8 pp+3.8 pp3rd least demanding of 10
ROIC minus cost of capital+25.9 pp-5.7 pp3rd highest of 14
EV / EBITDA36.0×15.8×3rd most expensive of 8
Net debt / EBITDA-3.9×-0.2×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%n/an/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%n/an/an/a
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a

Questions

Who are Krystal Biotech's main competitors?
Named competitors: Chiesi (Filsuvez, ex-Amryt) (private or unlisted), Abeona Therapeutics (ABEO), Ionis Pharmaceuticals (IONS). The cockpit's measured peer set (industry) also includes Vaxcyte (PCVX), ALTEOGEN (196170.KS), Genscript Biotech (1548.HK), Sichuan Kelun Pharmaceutical (002422.SZ), Kymera Therapeutics (KYMR), Summit Therapeutics (SMMT).
Is Krystal Biotech expensive compared with its peers?
On forward p/e it trades at 36.3× against a peer median of 34.4×, 4th most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Krystal Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned +4.4% against +23.8% for the median peer; over one year +51.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.